Philip Morris, Biogen, and Centene Post Q4 Earnings and 2026 Guidance
Philip Morris, Biogen, and Centene reported quarterly results, with PM and BIIB beating expectations and CNC posting mixed performance.
BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
BTC$62,686.00-1.67%
ETH$1,666.62-3.16%
USDT$0.9987-0.01%
USDC$0.9996-0.01%
XRP$1.10-1.88%
SOL$69.40-3.23%
TRX$0.329-1.01%
FIGR_HELOC$1.03-0.16%
HYPE$61.30-7.24%
DOGE$0.0789-3.56%
USDS$0.9997+0.00%
RAIN$0.0157-2.06%
LEO$9.49-0.84%
ZEC$413.84-6.89%
XLM$0.1911-3.05%
PM stock fell over 3% following its Q4 2025 earnings report, even as the company declared a $1.47 quarterly dividend and analysts broadly maintained bullish price targets .
Philip Morris, Biogen, and Centene reported quarterly results, with PM and BIIB beating expectations and CNC posting mixed performance.
Philip Morris International Inc. (PMI) reported record-breaking third-quarter net revenues driven by a strategic focus on smoke-free products.
UPS disappointed investors with weaker-than-expected performance, MSCI exceeded analyst expectations, while Philip Morris International raised its annual guidance due to strong sales of its Zyn nicotine…
Philip Morris International Inc. (PM) showcases resilience with a Q4 earnings per share (EPS) of $1.41, slightly under the forecasted $1.45.